Hollow Knight Silksong Development Was Hit Hard by Pandemic, Geoff Keighley Reveals

Table of Contents

In a recent interview, Geoff Keighley revealed that he had a conversation with Team Cherry, the developer behind Hollow Knight Silksong, and he thinks that the game was hit hard by the COVID-19 pandemic.

Recently, Geoff Keighly was interviewed by Gamespot, answering a series of questions about his personal life and favorites, though one of the questions was something that many gamers would like to learn more about: What is going on with the Hollow Knight Silksong development?

  • CHECK THIS OUT: Ark 2 Is Reportedly A Timed Xbox Exclusive and Will Come To PlayStation & Switch

Although Geoff Keighly made it clear that he has no information on where the game is now and when it can be ready to be published, he did provide some information about the struggles the development was faced in the last few years.

COVID Pandemic Should Be the One Big Reason Why We Haven’t Heard About Hollow Knight Silksong for a While

Geoff Keighley revealed that he has had talks with Team Cherry, and he thinks that the studio has been hit hard by the COVID-19 pandemic, forcing them to slow down the development process and take their time.

The last time we saw something official from Hollow Knight Silksong was back in 2019. That being said, William Pellen, co-director of Team Cherry, revealed in an interview with PC Gamer back in February 2022 that the development was still going on, and the team would share new details about the project when it gets closer to its launch.

Hollow Knight Silksong was originally revealed back in 2019. The game currently targets a launch on PC and Nintendo Switch. There is no information on whether it would be available on other platforms after launch, but the original Hollow Knight was released on PS4 and Xbox One almost a year after its launch on PC.

ncG1vNJzZmivp6x7pcHApaqhp5OgsrO%2FjZympmeYpLmtu9Zmoqehl53Bbr%2FIpaKsp56ceqWx1Z6jqKidmru1edaaqmagmal6qa3RnWSbsV2ptaZ5z5qlnZ2dnrBus8SonZ9lm5q2qLTLnrBmqpWrsqK40mg%3D